Novonesis Disappoints With New Midterm Margin Guidance -- Market Talk
Dow Jones08-21
0839 GMT - Biotechnology company Novonesis disappoints with a new midterm guidance for its adjusted Ebitda margin of around 39%, Citi analyst Ranulf Orr says in a research note. "Many investors we have spoken to expect the pricing model transformation to catalyze strong margin expansion, but it appears increased spend on uncertain long-horizon growth projects will undermine this," he says. Last year's company-complied consensus shows 2029 margin expectations of 40.6%, he adds. Shares trade 6.35% lower at 392.60 Danish kroner. (nina.kienle@wsj.com)
(END) Dow Jones Newswires
August 21, 2025 04:39 ET (08:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments